320 related articles for article (PubMed ID: 17968710)
1. Sirolimus inhibits human pancreatic carcinoma cell proliferation by a mechanism linked to the targeting of mTOR/HIF-1 alpha/VEGF signaling.
Wang Y; Zhao Q; Ma S; Yang F; Gong Y; Ke C
IUBMB Life; 2007 Nov; 59(11):717-21. PubMed ID: 17968710
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of PKHD1 may cause S-phase entry via mTOR signaling pathway.
Zheng R; Wang L; Fan J; Zhou Q
Cell Biol Int; 2009 Sep; 33(9):926-33. PubMed ID: 19524688
[TBL] [Abstract][Full Text] [Related]
3. Therapeutic strategy targeting the mTOR-HIF-1alpha-VEGF pathway in ovarian clear cell adenocarcinoma.
Miyazawa M; Yasuda M; Fujita M; Kajiwara H; Hirabayashi K; Takekoshi S; Hirasawa T; Murakami M; Ogane N; Kiguchi K; Ishiwata I; Mikami M; Osamura RY
Pathol Int; 2009 Jan; 59(1):19-27. PubMed ID: 19121088
[TBL] [Abstract][Full Text] [Related]
4. Silibinin inhibits hypoxia-inducible factor-1alpha and mTOR/p70S6K/4E-BP1 signalling pathway in human cervical and hepatoma cancer cells: implications for anticancer therapy.
García-Maceira P; Mateo J
Oncogene; 2009 Jan; 28(3):313-24. PubMed ID: 18978810
[TBL] [Abstract][Full Text] [Related]
5. Combination strategy targeting the hypoxia inducible factor-1 alpha with mammalian target of rapamycin and histone deacetylase inhibitors.
Verheul HM; Salumbides B; Van Erp K; Hammers H; Qian DZ; Sanni T; Atadja P; Pili R
Clin Cancer Res; 2008 Jun; 14(11):3589-97. PubMed ID: 18519793
[TBL] [Abstract][Full Text] [Related]
6. A quassinoid 6alpha-tigloyloxychaparrinone inhibits hypoxia-inducible factor-1 pathway by inhibition of eukaryotic translation initiation factor 4E phosphorylation.
Jin X; Jin HR; Lee D; Lee JH; Kim SK; Lee JJ
Eur J Pharmacol; 2008 Sep; 592(1-3):41-7. PubMed ID: 18639543
[TBL] [Abstract][Full Text] [Related]
7. Mammalian target of rapamycin: discovery of rapamycin reveals a signaling pathway important for normal and cancer cell growth.
Gibbons JJ; Abraham RT; Yu K
Semin Oncol; 2009 Dec; 36 Suppl 3():S3-S17. PubMed ID: 19963098
[TBL] [Abstract][Full Text] [Related]
8. Antiangiogenic potential of the Mammalian target of rapamycin inhibitor temsirolimus.
Del Bufalo D; Ciuffreda L; Trisciuoglio D; Desideri M; Cognetti F; Zupi G; Milella M
Cancer Res; 2006 Jun; 66(11):5549-54. PubMed ID: 16740688
[TBL] [Abstract][Full Text] [Related]
9. Targeting of mTOR is associated with decreased growth and decreased VEGF expression in acute myeloid leukaemia cells.
Böhm A; Aichberger KJ; Mayerhofer M; Herrmann H; Florian S; Krauth MT; Derdak S; Samorapoompichit P; Sonneck K; Vales A; Gleixner KV; Pickl WF; Sperr WR; Valent P
Eur J Clin Invest; 2009 May; 39(5):395-405. PubMed ID: 19320940
[TBL] [Abstract][Full Text] [Related]
10. Suppression of the proliferation of hypoxia-Induced retinal pigment epithelial cell by rapamycin through the /mTOR/HIF-1α/VEGF/ signaling.
Liu NN; Zhao N; Cai N
IUBMB Life; 2015 Jun; 67(6):446-52. PubMed ID: 25988388
[TBL] [Abstract][Full Text] [Related]
11. Effect of endothelial PAS domain protein 1 and hypoxia inducible factor 1alpha on vascular endothelial growth factor expression in human pancreatic carcinoma.
Zhu DM; Li DC; Zhang ZX; Zhang XY
Chin Med J (Engl); 2008 Nov; 121(22):2258-64. PubMed ID: 19080330
[TBL] [Abstract][Full Text] [Related]
12. Differential effects of rapamycin on mammalian target of rapamycin signaling functions in mammalian cells.
Edinger AL; Linardic CM; Chiang GG; Thompson CB; Abraham RT
Cancer Res; 2003 Dec; 63(23):8451-60. PubMed ID: 14679009
[TBL] [Abstract][Full Text] [Related]
13. AKT activity regulates the ability of mTOR inhibitors to prevent angiogenesis and VEGF expression in multiple myeloma cells.
Frost P; Shi Y; Hoang B; Lichtenstein A
Oncogene; 2007 Apr; 26(16):2255-62. PubMed ID: 17016437
[TBL] [Abstract][Full Text] [Related]
14. An activated mTOR/p70S6K signaling pathway in esophageal squamous cell carcinoma cell lines and inhibition of the pathway by rapamycin and siRNA against mTOR.
Hou G; Xue L; Lu Z; Fan T; Tian F; Xue Y
Cancer Lett; 2007 Aug; 253(2):236-48. PubMed ID: 17360108
[TBL] [Abstract][Full Text] [Related]
15. Granulosa cell tumor with activated mTOR-HIF-1alpha-VEGF pathway.
Miyazawa M; Yasuda M; Fujita M; Hirabayashi K; Hirasawa T; Kajiwara H; Muramatsu T; Miyazaki S; Harasawa M; Matsui N; Ogane N; Murakami M; Mikami M; Yanase T; Osamura RY
J Obstet Gynaecol Res; 2010 Apr; 36(2):448-53. PubMed ID: 20492406
[TBL] [Abstract][Full Text] [Related]
16. mTOR inhibitor RAD001 (everolimus) has antiangiogenic/vascular properties distinct from a VEGFR tyrosine kinase inhibitor.
Lane HA; Wood JM; McSheehy PM; Allegrini PR; Boulay A; Brueggen J; Littlewood-Evans A; Maira SM; Martiny-Baron G; Schnell CR; Sini P; O'Reilly T
Clin Cancer Res; 2009 Mar; 15(5):1612-22. PubMed ID: 19223496
[TBL] [Abstract][Full Text] [Related]
17. [Inhibition of hypoxia-inducible factor 1alpha expression and tumor growth in SKOV3 ovarian cancer model by sirolimus].
Jiang HY; Feng YJ
Zhonghua Fu Chan Ke Za Zhi; 2004 Jul; 39(7):474-7. PubMed ID: 15347472
[TBL] [Abstract][Full Text] [Related]
18. Rapamycin inhibits growth of premalignant and malignant mammary lesions in a mouse model of ductal carcinoma in situ.
Namba R; Young LJ; Abbey CK; Kim L; Damonte P; Borowsky AD; Qi J; Tepper CG; MacLeod CL; Cardiff RD; Gregg JP
Clin Cancer Res; 2006 Apr; 12(8):2613-21. PubMed ID: 16638874
[TBL] [Abstract][Full Text] [Related]
19. [Mammalian target of rapamycin, its mode of action and clinical response in metastatic clear cell carcinoma].
Shuuin T; Karashima H
Gan To Kagaku Ryoho; 2009 Jul; 36(7):1076-9. PubMed ID: 19620795
[TBL] [Abstract][Full Text] [Related]
20. Rapamycin induces the fusion-type independent downregulation of the EWS/FLI-1 proteins and inhibits Ewing's sarcoma cell proliferation.
Mateo-Lozano S; Tirado OM; Notario V
Oncogene; 2003 Dec; 22(58):9282-7. PubMed ID: 14681687
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]